The prevalent strain of COVID-19 is mild and the Serum Institute of India (SII) has already produced five to six million doses of the Covovax vaccine, said the company's chief executive officer Adar Poonawalla.
The DCGI had approved Covovax for restricted use in emergency situations in adults on December 28, 2021, in the 12-17 age group on March 9, 2022, and in the 7-11 age group on June 28, 2022, subject to certain conditions.
NVAX may remain volatile in the short term due to the $700M Advance Purchase Agreement dispute with GAVI. Click here to read my most recent analysis of NVAX.
Speaking to reporters on the sidelines of an event at Bharti Vidyapeeth University, Poonawalla, when asked about states and districts not getting Covishield vaccines, said there are ample stocks with the Union government for supply